COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference
Magdalena to submit IND application for psychoactive drug candidate for mental health indications. MB2500 aims to treat cognitive deficit in schizophrenia and ADHD. Magdalena focuses on safe, plant-based drugs under FDA Botanical Guidance -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Announces First Patient Dosed in Short Bowel Syndrome with Intestinal Failure in Investigator-Initiated Trial of Crofelemer; Proof-of-Concept Data Potentially Available H1 2025
Sheikh Khalifa Medical City hosts trial for Jaguar's crofelemer, plant-based drug granted Orphan Drug Designation. Study could lead to early patient access in Europe for rare diseases -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Supports Evaluation of FDA-Approved Crofelemer to Address GI Side Effects of GLP-1 and Other Weight Loss Therapies: Files Patent Application with USPTO
Napo Pharmaceuticals files provisional patent application with USPTO for crofelemer, a novel plant-based drug to mitigate GI side effects of GLP-1 therapies
